Association of Serum Ustekinumab Levels With Clinical Response in Psoriasis.

Clicks: 237
ID: 47240
2019
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
High-cost biologic therapies have transformed the management of immune-mediated inflammatory diseases. To optimize outcomes and reduce costs, dose adjustment informed by measurement of circulating drug levels has been shown to be effective in various settings. However, limited evidence exists for this approach with the interleukin 12 and interleukin 23 inhibitor ustekinumab.To evaluate clinical utility of therapeutic drug monitoring for ustekinumab in patients with psoriasis.A prospective observational cohort of 491 adults with psoriasis was recruited to the multicenter Biomarkers of Systemic Treatment Outcomes in Psoriasis study within the British Association of Dermatologists Biologic and Immunomodulators Register from June 2009 to December 2017; samples from some patients were taken between 2009 and 2011 as part of a pilot study with the same inclusion criteria.Serum ustekinumab level measured at any point during the dosing cycle using an enzyme-linked immunosorbent assay.Disease activity measured using the Psoriasis Area and Severity Index (PASI) score. Treatment response outcomes were PASI75 (75% reduction in PASI score from baseline [primary outcome]), PASI90 (90% reduction of PASI score from baseline), and absolute PASI score of 1.5 or less.A total of 491 patients (171 women and 320 men; mean [SD] age, 45.7 [12.8] years) had 1 or more serum samples (total, 853 samples obtained 0-56 weeks from start of treatment) and 1 or more PASI scores within the first year of treatment. Antidrug antibodies were detected in only 17 of 490 patients (3.5%). Early measured drug levels (1-12 weeks after starting treatment) were associated with PASI75 response 6 months after starting treatment (odds ratio, 1.38; 95% CI, 1.11-1.71) when adjusted for baseline PASI score, age, and ustekinumab dose. However, this finding was not consistent across the other PASI outcomes (PASI90 and PASI score of ≤1.5).This real-world study provides evidence that measurement of early serum ustekinumab levels could be useful to direct the treatment strategy for psoriasis. Adequate drug exposure early in the treatment cycle may be particularly important in determining clinical outcome.
Reference Key
tsakok2019associationjama Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Tsakok, Teresa;Wilson, Nina;Dand, Nick;Loeff, Floris C;Bloem, Karien;Baudry, David;Duckworth, Michael;Pan, Shan;Pushpa-Rajah, Angela;Standing, Joseph F;de Vries, Annick;Alsharqi, Ali;Becher, Gabrielle;Murphy, Ruth;Wahie, Shyamal;Wright, Andrew;Griffiths, Christopher E M;Reynolds, Nick J;Barker, Jonathan;Warren, Richard B;Burden, A David;Rispens, Theo;Stocken, Deborah;Smith, Catherine;, ;
Journal jama dermatology
Year 2019
DOI 10.1001/jamadermatol.2019.1783
URL
Keywords

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.